Multicenter Phase II Clinical Study on the Safety and Efficacy of Nilotinib in Patients with Chronic Myelogenous Leukemia, Chronic Phase Patients with Major Molecular Response.

Trial Profile

Multicenter Phase II Clinical Study on the Safety and Efficacy of Nilotinib in Patients with Chronic Myelogenous Leukemia, Chronic Phase Patients with Major Molecular Response.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms STAT1
  • Most Recent Events

    • 25 Jun 2017 Results of association of nilotinib trough concentraion and liver dysfunction data from two studies (STAT1 and STAT2) presented at the 22nd Congress of the European Haematology Association
    • 08 Dec 2015 Status changed from active, no longer recruiting to completed as reported by the results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top